On May 10, 2018 FORMA Therapeutics (FORMA), a fully-integrated research and development biotechnology company, reported an abstract featuring the company’s selective, small molecule IDH1m inhibitor, FT-2102, has been selected for an oral presentation at the upcoming 2018 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which will be held from June 1-5, 2018 in Chicago, Illinois (Press release, Forma Therapeutics, MAY 10, 2018, View Source [SID1234526429]). Details on the presentation are included below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date and Time: Monday, June 4, 2018, 4:30 PM – 6:00 PM

Session Title: Targeted Therapy in Leukemia

Session Type: Oral Abstract Session Title: A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Abstract No.: 7009